Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cells + IL-2 for Relapse Prevention in AML/MDS/MPN Post-Transplant
NCT06138587Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2024
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Myeloproliferative Neoplasm (MPN), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 6 weeks. Started Jan 2024; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT06138587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138587.